Alastin Skincare Receives Fourth U.S. Patent for Its TriHex Technology

INhance Post-Injection Serum

The United States Patent and Trademark Office has issued a fourth U.S. Patent (No. 10,688,147) for ALASTIN Skincare's TriHex Technology. The patent is directed to INhance Post-Injection Serum with TriHex Technology, a topical composition for alleviating bruising caused by a cosmetic procedure.

“We are immensely proud of the scientific investment we have made in validating TriHex Technology performance in our product formulations which is confirmed by its numerous patents. INhance Post-Injection Serum combines the anti-aging benefits of patented TriHex Technology and our new ChromaFADE Technology to deliver state of the art post-procedure recovery and skin enhancing benefits,” said Alan Widgerow, MD, FACS, chief medical officer at ALASTIN.

“I love the new INhance Post-Injection Serum with TriHex Technology. It has improved patient satisfaction with injectable procedures as a result of noticeable reductions in black and blue color of the bruise and postprocedure swelling. The added antiaging benefits of TriHex Technology in supporting the skin’s ability to create new collagen and elastin make the addition of INhance Post-Injection Serum a must-have in any aesthetic practice,” said Shino Bay Aguilara, DO of Shino Bay Cosmetic Dermatology and Laser Institute in Ft. Lauderdale, Florida.

More in News